Pharsight

1. Exelon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US4948807	NOVARTIS	Phenyl carbamates	Aug, 2012 (11 years ago)

Drugs and Companies using RIVASTIGMINE TARTRATE ingredient

Market Authorisation Date: 21 April, 2000

Treatment: Treatment of alzheimer's dementia

Dosage: CAPSULE;ORAL; SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1.5 mg, 3 mg, 4.5 mg and 6 mg	21 Apr, 2004	3	22 Oct, 2007	11 Feb, 2014	Eligible
2 mg/mL	05 Nov, 2004	1		11 Feb, 2014	Extinguished

Strength	Dosage	Availability
EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 2MG BASE/ML	SOLUTION;ORAL	Discontinued
EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued

EXELON family patents

2. Exelon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US4948807	SANDOZ	Phenyl carbamates	Aug, 2012 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 27, 2016
New Strength(NS)	Aug 31, 2015

Drugs and Companies using RIVASTIGMINE ingredient

Market Authorisation Date: 06 July, 2007

Treatment: Treatment of alzheimer's dementia

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
4.6 mg/24 hr and 9.5 mg/24 hr	27 Apr, 2011	1		08 Jan, 2019	Extinguished
13.3 mg/24 hr	22 Jan, 2013	1	31 Aug, 2015	08 Jan, 2019	Eligible

Strength	Dosage	Availability
9.5MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
4.6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

EXELON family patents

3. Geodon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5312925	VIATRIS	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride	Sep, 2012 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-232)	Jan 28, 2025
New Indication(I-615)	Nov 20, 2012

Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 February, 2001

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg, 40 mg, 60 mg and 80 mg	07 Feb, 2005	5	02 Mar, 2012	27 May, 2019	Eligible

Strength	Dosage	Availability
EQ 20MG BASE	CAPSULE;ORAL	Prescription
EQ 80MG BASE	CAPSULE;ORAL	Prescription
EQ 40MG BASE	CAPSULE;ORAL	Prescription
EQ 60MG BASE	CAPSULE;ORAL	Prescription

GEODON family patents

4. Geodon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5312925	PFIZER INC	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride	Sep, 2012 (11 years ago)

Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 March, 2006

Treatment: Treatment of neuroleptic diseases

Dosage: SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg, 40 mg, 60 mg and 80 mg	07 Feb, 2005	5	02 Mar, 2012	27 May, 2019	Eligible

Strength	Dosage	Availability
EQ 10MG BASE/ML	SUSPENSION;ORAL	Discontinued

GEODON family patents

5. Latisse patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6403649	ABBVIE	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Sep, 2012 (11 years ago)
US8017655	ABBVIE	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Nov, 2012 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 24, 2011
M(M-140)	Sep 04, 2017

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 24 December, 2008

Treatment: NA

Dosage: SOLUTION/DROPS;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0003	03 May, 2010	1	01 Dec, 2014	25 May, 2024	Extinguished Deferred

Strength	Dosage	Availability
0.03%	SOLUTION/DROPS;TOPICAL	Prescription

LATISSE family patents

6. Lumigan patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6403649	ABBVIE	Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Sep, 2012 (11 years ago)
US8017655	ABBVIE	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents	Nov, 2012 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 31, 2013

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 31 August, 2010

Treatment: Topical treatment of ocular hypertension and glaucoma

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0001	05 Apr, 2011	1		13 Jun, 2027
0.0003	22 Dec, 2008	1			Extinguished

Strength	Dosage	Availability
0.01%	SOLUTION/DROPS;OPHTHALMIC	Prescription
0.03% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION/DROPS;OPHTHALMIC	Discontinued

LUMIGAN family patents

7. Prezista patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6335460	JANSSEN PRODS	α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors	Aug, 2012 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Jun 16, 2015
New Dosage Form(NDF)	Dec 16, 2014
New Dosing Schedule(D-135)	Feb 01, 2016

Drugs and Companies using DARUNAVIR ingredient

Market Authorisation Date: 16 December, 2011

Treatment: Treatment of human immunodeficiency virus (hiv) infection in adult patients, and treatment of human immunodeficiency virus (hiv) in pediatric patients 6 years of age and older

Dosage: SUSPENSION;ORAL; TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mg, 150 mg and 300 mg	23 Jun, 2010	1		26 Dec, 2026
400 mg	23 Jun, 2010	3		26 Dec, 2026
600 mg	23 Jun, 2010	4	21 Nov, 2017	26 Dec, 2026	Deferred
800 mg	14 May, 2013	1	29 Sep, 2022	26 Dec, 2026	Eligible

Strength	Dosage	Availability
100MG/ML	SUSPENSION;ORAL	Prescription
800MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription
400MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
600MG	TABLET;ORAL	Prescription
300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
75MG	TABLET;ORAL	Prescription

PREZISTA family patents

8. Proscar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5886184	ORGANON	Finasteride processes	Nov, 2012 (11 years ago)

Drugs and Companies using FINASTERIDE ingredient

Market Authorisation Date: 19 June, 1992

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription

PROSCAR family patents

9. Reclast patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US4939130	SANDOZ	Substituted alkanediphosphonic acids and pharmaceutical use	Sep, 2012 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-595)	May 29, 2012
New Indication(I-581)	Dec 19, 2011
New Indication(I-584)	Mar 15, 2012

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 16 April, 2007

Treatment: Treatment of osteoporosis in postmenopausal women

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.05 mg/mL, 100 mL vial	29 Aug, 2008	1		02 Sep, 2012	Extinguished

Strength	Dosage	Availability
EQ 5MG BASE/100ML	INJECTABLE;INTRAVENOUS	Prescription

RECLAST family patents

10. Rescula patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5221763	SUCAMPO PHARMA LLC	Prostaglandins of the F series	Jul, 2012 (11 years ago)

Drugs and Companies using UNOPROSTONE ISOPROPYL ingredient

Market Authorisation Date: 03 August, 2000

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0015	12 May, 2014	1		09 Jul, 2021	Extinguished

Strength	Dosage	Availability
0.15% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION/DROPS;OPHTHALMIC	Discontinued

RESCULA family patents

11. Sustiva patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5811423	BRISTOL MYERS SQUIBB	Benzoxazinones as inhibitors of HIV reverse transcriptase	Aug, 2012 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	May 02, 2016
Pediatric Exclusivity(PED)	Nov 02, 2016

Drugs and Companies using EFAVIRENZ ingredient

Market Authorisation Date: 17 September, 1998

Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
600 mg	09 Apr, 2009	1	17 Feb, 2016	20 Jan, 2018	Eligible
50 mg, 100 mg and 200 mg	03 Nov, 2016	1	15 Dec, 2017	06 Apr, 2019	Eligible

Strength	Dosage	Availability
100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
200MG	CAPSULE;ORAL	Discontinued
50MG	CAPSULE;ORAL	Discontinued

SUSTIVA family patents

12. Tikosyn patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US4959366	PFIZER	Anti-arrhythmic agents	Sep, 2012 (11 years ago)

Drugs and Companies using DOFETILIDE ingredient

Market Authorisation Date: 01 October, 1999

Treatment: Treatment of cardiac arrhythmia

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.125 mg, 0.25 mg, and 0.5 mg	01 May, 2014	1	06 Jun, 2016	09 Oct, 2018	Eligible

Strength	Dosage	Availability
0.5MG	CAPSULE;ORAL	Prescription
0.125MG	CAPSULE;ORAL	Prescription
0.25MG	CAPSULE;ORAL	Prescription

TIKOSYN family patents

13. Zometa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US4939130	NOVARTIS	Substituted alkanediphosphonic acids and pharmaceutical use	Sep, 2012 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Sep 20, 2011

Drugs and Companies using ZOLEDRONIC ACID ingredient

Market Authorisation Date: 20 August, 2001

Treatment: Hypercalcemia of malignancy

Dosage: INJECTABLE;INTRAVENOUS

Pharsight

Drug Patents Expiring in 2012

1. Exelon patents expiration

EXELON family patents

2. Exelon patents expiration

EXELON family patents

3. Geodon patents expiration

GEODON family patents

4. Geodon patents expiration

GEODON family patents

5. Latisse patents expiration

LATISSE family patents

6. Lumigan patents expiration

LUMIGAN family patents

7. Prezista patents expiration

PREZISTA family patents

8. Proscar patents expiration

PROSCAR family patents

9. Reclast patents expiration

RECLAST family patents

10. Rescula patents expiration

RESCULA family patents

11. Sustiva patents expiration

SUSTIVA family patents

12. Tikosyn patents expiration

TIKOSYN family patents

13. Zometa patents expiration

ZOMETA family patents

Related content

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.8 mg (base) /mL	11 Jun, 2008	1		02 Sep, 2012	Extinguished
4 mg/100 mL, 100 mL vial	31 Jan, 2012	1		05 Feb, 2028	Extinguished

Strength	Dosage	Availability
EQ 4MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INTRAVENOUS	Discontinued
EQ 4MG BASE/100ML	INJECTABLE;INTRAVENOUS	Discontinued
EQ 4MG BASE/5ML	INJECTABLE;INTRAVENOUS	Discontinued